{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:15:42Z","timestamp":1785273342608,"version":"3.55.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.15668","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:55:11Z","timestamp":1625788511000},"page":"e2115668","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies"],"prefix":"10.1001","volume":"4","author":[{"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, San Francisco General Hospital, San Francisco, California"},{"name":"Department of Hematology Oncology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"issue":"8","key":"zoi210467r1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi210467r2","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"6","key":"zoi210467r3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors.","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"zoi210467r4","author":"Neelapu","year":"2020"},{"issue":"2","key":"zoi210467r5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ymthe.2017.10.019","article-title":"CAR-T Cells: a systematic review and mixed methods analysis of the clinical trial landscape.","volume":"26","author":"Pettitt","year":"2018","journal-title":"Mol Ther"},{"issue":"2","key":"zoi210467r6","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000188","article-title":"CAR-T cells: future perspectives.","volume":"3","author":"Charrot","year":"2019","journal-title":"Hemasphere"},{"issue":"8","key":"zoi210467r7","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1002\/ijc.v144.8","article-title":"The landscape of CAR T-cell therapy in the United States and China: a comparative analysis.","volume":"144","author":"Gou","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"zoi210467r8","article-title":"Current landscape (at March 2019) of chimeric antigen receptor T cell clinical trials.","volume":"14","author":"I\u00f1aki","year":"2019","journal-title":"Adv Biotechnol Microbiol"},{"issue":"9","key":"zoi210467r9","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3390\/cancers12092567","article-title":"The landscape of CAR-T Cell clinical trials against solid tumors\u2014a comprehensive overview.","volume":"12","author":"Schaft","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"zoi210467r10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors.","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"12","key":"zoi210467r11","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s41587-020-00749-8","article-title":"The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape.","volume":"38","author":"Lyu","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"7","key":"zoi210467r12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"7","key":"zoi210467r24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.12119","article-title":"Are observational, real-world studies suitable to make cancer treatment recommendations?","volume":"3","author":"Banerjee","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi210467r25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome.","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"zoi210467r26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2020006216","article-title":"Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?","volume":"136","author":"Frigault","year":"2020","journal-title":"Blood"},{"issue":"27","key":"zoi210467r27","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium.","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"zoi210467r13","unstructured":"A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application. ClinicalTrials.gov identifier: NCT02980315. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02980315"},{"key":"zoi210467r14","unstructured":"Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed\/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7). ClinicalTrials.gov identifier: NCT03391466. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03391466"},{"key":"zoi210467r15","unstructured":"Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC. ClinicalTrials.gov identifier: NCT03525782. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03525782"},{"key":"zoi210467r16","unstructured":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA). ClinicalTrials.gov identifier: NCT03570892. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03570892"},{"key":"zoi210467r17","unstructured":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). ClinicalTrials.gov identifier: NCT03575351. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03575351"},{"key":"zoi210467r18","unstructured":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3). ClinicalTrials.gov identifier: NCT03651128. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03651128"},{"key":"zoi210467r19","unstructured":"Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir. ClinicalTrials.gov identifier: NCT03980691. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03980691"},{"key":"zoi210467r20","unstructured":"Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases. ClinicalTrials.gov identifier: NCT04037241. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04037241"},{"key":"zoi210467r21","unstructured":"B7-H3 CAR-T for Recurrent or Refractory Glioblastoma. ClinicalTrials.gov identifier: NCT04077866. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04077866"},{"key":"zoi210467r22","unstructured":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). ClinicalTrials.gov identifier: NCT04181827. Accessed May 24, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04181827"},{"key":"zoi210467r23","unstructured":"Janssen Pharmaceutical Companies. Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and\/or Refractory Multiple Myeloma. Published December 21, 2020. Accessed December 26, 2020. https:\/\/www.janssen.com\/janssen-initiates-rolling-submission-biologics-license-application-us-fda-bcma-car-t-therapy"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2781725\/banerjee_2021_oi_210467_1624907966.7571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:55:25Z","timestamp":1625788525000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2781725"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.15668","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}